CD4 T-cell immunotherapy targeting MAGE-A3 is safe, and shows early clinical responses
CD4 T-cell immunotherapy targeting MAGE-A3 is safe, and shows early clinical responses
New investigational targeted therapeutic, entrectinib, shows early promise
Targeting T regs in tumours
Multiplex IHC as biomarkers for cancer immunotherapy
Direct activation of STING in the tumour microenvironment leads to potent and systemic tumour regression and immunity
Successes and challenges in designing combination immunotherapy clinical trials for breast cancer
Inflammatory microenvironment regulates colorectal cancer progression
Mechanisms of immune escape in non-Hodgkin lymphoma
'Helper' T Cells effective in therapy, and shows early clinical responses in patients with metastatic cancer
Technologies for personalised cancer immunotherapies
Modulating the DNA damage response: The role of cell cycle checkpoint inhibitors
Comment on RESONATE2 and CLL115 trials